1-fluoro-4-isopropylbicyclo<2.2.2>octane | 81687-83-4

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: 1-fluoro-4-isopropylbicyclo<2.2.2>octane
• 英文别名: 1-Fluoro-4-propan-2-ylbicyclo[2.2.2]octane
• CAS: 81687-83-4
• 化学式: C₁₁H₁₉F
• 分子量: 170.27
• InChiKey: HNPJSOIHGKRMDL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-(1-Chloro-1-methyl-ethyl)-4-fluoro-bicyclo[2.2.2]octane 在 lithium 、 叔丁醇 作用下， 以 四氢呋喃 为溶剂， 生成 1-fluoro-4-isopropylbicyclo<2.2.2>octane
  参考文献：
  名称：

  Synthesis of 4-substituted bicyclo[2.2.2]oct-1-yl fluorides

  摘要：

  DOI：

  10.1021/jo00136a028

文献信息

• ADCOCK, W.;ABEYWICKREMA, A. N., J. ORG. CHEM., 1982, 47, N 15, 2951-2957
  作者：ADCOCK, W.、ABEYWICKREMA, A. N.

  DOI：——

  日期：——
• COMPOUNDS AND USES THEREOF
  申请人：Yumanity Therapeutics, Inc.

  公开号：US20200262828A1

  公开（公告）日：2020-08-20

  The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
• CYCLIN-DEPENDENT KINASE INHIBITORS
  申请人：SPV THERAPEUTICS INC.

  公开号：US20220056037A1

  公开（公告）日：2022-02-24

  Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are useful in the treatment or alleviation of protein kinase associated disorders, including cancer, infectious diseases, autoimmune diseases, or cardiovascular diseases.
• LPA RECEPTOR ANTAGONISTS AND USES THEREOF
  申请人：Gilead Sciences, Inc.

  公开号：US20220411406A1

  公开（公告）日：2022-12-29

  The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).